Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure

International Heart Journal

Volumn 47, Issue 4, 2006, Pages 565-573

  Akdeniz, Bahri ^a   Guneri, Sema ^a   Savas, Ilke Z ^a   Aslan, Özgür ^a   Baris, Nezihi ^a   Badak, O Ozer ^a   Kirimli, Önder ^a   Göldeli, Özhan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Carvedilol; Heart failure; Heart rate variability; QT dispersion

Indexed keywords

CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; NITRATE; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART RATE VARIABILITY; HEART VENTRICLE; HOLTER MONITORING; HUMAN; MALE; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT DISPERSION; REPOLARIZATION; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ARRHYTHMIA; CARBAZOLES; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749133808     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.47.565     Document Type: Article

References (32)

1. Narang R, Celand JG, Erhardt L, et al. Mode of death in chronic hearth failure. A request and proposition for more accurate classifications. Eur Heart J 1996; 17: 1398-403. (Review)
2. Parmley WW, Chatterjee K. Congestive heart failure and arrhythmias: an overview. Am J Cardiol 1986; 57: 34B-7.
3. Bigger JT Jr. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 1987; 75: IV28-35. (Review)
4. Periomaki JS, Koisitinen MJ, Yli-Mayry S, Huikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995: 26; 174-9.
5. Vasallo JA, Cassidy DM, Kindwall KE, Marchlinski FE, Josephson ME. Nonuniform recovery of excitability in the left ventricle. Circulation 1988; 78: 1365-72.
6. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63: 342-4.
7. Heart rate variability: standards of measurements, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93: 1043-65.
8. Bonnar CE, Davie AP, Caruana L, et al. QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. Heart 1999; 81: 297-302.
9. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-55.
10. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double blind, placebo-controlled, randomized trials. Circulation 1998; 98:1184-91.
11. Hiroi Y, Fljiu K, Komatsu S, et al. Carvedilol therapy improved left ventricular function in a patient with arrhythmogenic right ventricular cardiomyopathy. Jpn Heart J 2004; 45: 169-77.
12. Yildirir A, Sade E, Tokgozoglu L, Oto A. The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. Eur J Heart Fail 2001; 3: 717-21.
13. Fesmire SI, Marcoux LG, Lyyski DS, Sprague MK, Kennedy HL, Eichhorn EJ. Effect of selective versus non-selective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Am J Cardiol 1999; 84: 350-4.
14. Mortara A, La Rovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F. Nonselective beta adrenergic blocking agent carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure J Am Coll Cardiol 2000; 36: 1612-8.
15. Bazzet HC. An analysis of time relation of electrocardiogram. Heart 1920; 28: 67-73.
16. Kuo CS, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential duration. Circulation 1983; 67: 1356-67.
17. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327-9.
18. Higham PD, Furniss SS, Campbell RW. QT dispersion and components of the QT interval in ischaemia and infarction. Br Heart J 1995; 73: 32-6.
19. Etheridge SP, Shaddy RE. QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure. Am J Cardiol 2003; 91: 1497-500.
20. Jepson N, Farshid A, Friend C, Allan R, Walsh W. Carvedilol reduces QT interval dispersion in patients with chronic heart failure. J Am Coll Cardiol 1999; 33: 200A. (abstract)
21. Pittenger B, Gill EA, Holcslaw TL, Bristow MR. Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. Am J Cardiol 2004; 94: 1459-62.
22. Rocha RM, Silva GM, Perin EC, et al. Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? Tex Heart Inst J 2003; 30: 176-9.
23. Grassi G, Cattaneo BM, Mancia G. Sympathetic nervous system. In: Poole-Wilson PA, editor. Heart Failure. New York: Churchill Livingstone, 1997: 199-214.
24. Weiss R, Feery D, Pickering E, et al. Effectiveness of three different doses of carvedilol for exertional angina. Am J Cardiol 1998; 82: 927-31.
25. Mesquita ET, Deus FC, Guedes CR, et al. Effects of propranolol on the QT dispersion in congestive heart failure. Arq Bras Cardiol 1999; 73: 295-8.
26. Peng DQ, Zhao SP, Chen Y, Li XP. Effect of bisoprolol on QT dispersion in patients with congestive heart failure - the etiology-dependent response. Int J Cardiol 2001; 77: 141-8; discussion 148-9.
27. Lombardi F, Mortara A. Heart rate variability and cardiac failure. Heart 1998; 80: 213-4. (Review)
28. Adamson PB, Huang MH, Vanoli E, Foreman RD, Schwartz PJ, Hull SS Jr. Unexpected interaction between β-adrenergic blockade and heart rate variability before and after myocardial infarction. A longitudinal study in dogs at high and low risk for sadden death. Circulation 1994; 90: 976-82.
29. Bigger JT Jr, Kleiger RE, Fleiss JL, Rolnitzky LM, Steimnan RC, Miller JP. Components of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol 1988; 61: 208-15.
30. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998; 98: 1510-6.
31. Goldsmith RL, Bigger TJ, Bloomfield DM, et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 1997; 80: 1101-4.
32. Sanderson JE, Yeung LY, Chan S, et al. Effect of beta-blockade on baroreceptor and autonomic function in heart failure. Clin Sci 1999; 96: 13746.